=== PAGE 4 ===

COMPLETE PAGE ANALYSIS:
--------------------------------------------------
Here is the extracted text content from the PDF page, preserving its original layout and structure:

<img of Nascent Biotech Inc. logo - a stylized blue shape resembling a double helix or abstract "NB"> NASCENT
       BIOTECH, INC.

                                                                               Products Investors News About Contact

Pritumumab
has received FDA orphan
drug status

Delivering human antibodies for the treatment of cancer

<image of a 3D molecular structure, likely representing an antibody, composed of multiple interconnected lobes in shades of green, blue, and purple>

Pritumumab                                             Latest News

Learn more about Nascent Biotech's primary drug product,  JUNE 3, 2019
Pritumumab.                                            Nascent CEO Sean Carrick On RedChip Money Report

NBIO Stock Information                                 MARCH 10, 2019
                                                       Human Antibodies: Antibody drug conjugates: Progress, pitfalls, and
NBIO: (%)                                              promises

Investor Presentation                                  DECEMBER 11, 2018
                                                       Nascent Biotech Receives Clearance from FDA to Begin Phase I Human
Download Investor Presentation                         Trials in Brain Cancer

Email Updates                                          JULY 27, 2018
                                                       Prionogenicity of vimentin surmised from the sequelog of anti-idiotypic
<envelope icon> Subscribe Now                          antibodies toward the paratope of malignant associated autologous anti-
                                                       vimentin antibody, CLN-IgG (Pritumumab)

                                                       APRIL 4, 2018
                                                       Nascent Biotech to Sponsor Human Antibodies & Hybridomas
                                                       Conference

Copyright Nascent Biotech. All rights reserved.
